Skip to main content
search

(VIDEO) UCI MIND researchers use human stem cell models to understand immunity in Alzheimer’s disease

Amanda McQuade, graduate student in Mathew Blurton-Jones’ lab at UCI MIND, discusses findings from their new study using induced pluripotent stem cells (iPSC), donated from participants at the UCI Alzheimer’s Disease Research Center, and CRISPR gene editing to improve understanding of the role of immunity in Alzheimer’s disease. Click below to view the video, and access the publication at this link: https://www.nature.com/articles/s41467-020-19227-5

 

 

Amanda McQuade, MS

Amanda McQuade is a graduate student in the department of Neurobiology and Behavior working with Dr. Mathew Blurton-Jones. Her graduate work focuses on using CRISPR to study risk mutations for Alzheimer’s disease in human cell models and chimeric animal models. Her ongoing studies highlight the critical need for more research into immune function in neurodegenerative disease. McQuade is currently acting as a Co-Chair of the trainee program on Research and education within UCI MIND, ReMIND, which focuses on community outreach and trainee education.

Related posts:

  1. Keeping sleep in mind: poor sleep and dementia risk A recent article in the New York Times, How Poor Sleep Affects Your Risk of Dementia, summarizes some recent findings showing both excessively short and long sleep, as well as sleep disorders such as sleep apnea, insomnia, and rapid-eye movement (REM) behavior disorder, may be linked with risk for Alzheimer’s...
  2. Listening to patients unable to communicate The New York Times recently covered a remarkable study published in the New England Journal of Medicine. The study performed clinical and imaging assessments of 353 adults deemed to be in a minimally conscious or persistent vegetative state. These individuals, who had experienced severe brain injury, stroke, or hypoxia after...
  3. On the NYT article “What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials” An article in the New York Times is the latest to highlight the safety risks associated with recently approved new treatments for Alzheimer’s disease, lecanemab and donanemab. Being a carrier of the e4 genotype for the apolipoprotein (APOE) gene, is a known risk factor for the most serious side effects...
Close Menu